Sugi Predict

Sugi Predict / Compounds / SCHEMBL934211

SCHEMBL934211

SCHEMBL934211

CS(=O)(=O)c1cccc(OBOc2cccc(S(C)(=O)=O)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.44
▸ CRBN Q96SW2 1/20 0.44
▸ NR1H2 P55055 9/20 0.42
▸ NR1H3 Q13133 9/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ GCK P35557 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.37
▸ KEAP1 Q14145 1/20 0.37
▸ NFE2L2 Q16236 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900979 0.85 DDB1 (0.43) DDB1CRBNNR1H2NR1H3SMN1; SMN2
SCHEMBL3995696 0.81 NFE2L2 (0.39) FFAR4KEAP1NFE2L2
SCHEMBL645132 0.81 PSIP1 (0.48) NR1H2NR1H3
SCHEMBL3335415 0.81 CA2 (0.59) —
SCHEMBL15303538 0.80 L3MBTL1 (0.50) SMN1; SMN2FFAR4KEAP1NFE2L2
SCHEMBL803706 0.80 NFE2L2 (0.54) SMN1; SMN2FFAR4KEAP1NFE2L2
SCHEMBL29650302 0.80 NFE2L2 (0.54) SMN1; SMN2FFAR4KEAP1NFE2L2
SCHEMBL2537921 0.78 DDB1 (0.46) DDB1CRBNNR1H2NR1H3SMN1; SMN2
SCHEMBL14018981 0.77 NR1H2 (0.55) NR1H2NR1H3SMN1; SMN2GCK
SCHEMBL8478768 0.76 MAPT (0.61) SMN1; SMN2FFAR4KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
CN-118119600-A SOS1 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-05-31 — — CN disclosed
CN-117050072-B Pyrazolopyridine derivative and application thereof 沈阳药科大学 2024-05-17 — — CN disclosed
CN-112654608-B Fused ring compound having urea structure 桑福德伯纳姆普利斯医学发现研究所 2024-05-07 — — CN disclosed
CN-113840820-B Phthalazinone compounds and uses thereof ST制药株式会社 2024-05-03 — — CN disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
CN-117043162-A TYK2 selective inhibitors and uses thereof 迈巴制药(南京)有限公司 2023-11-10 — — CN disclosed
US-20230212127-A1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS, INC. 2023-07-06 — — US disclosed
CN-115991706-A PIM kinase inhibitors 杭州邦顺制药有限公司 2023-04-21 — — CN disclosed
CN-115916748-A Indole derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) 弗特克斯药品有限公司 2023-04-04 — — CN disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 — — US disclosed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 — — WO disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 — — WO disclosed
WO-2006019833-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-02-23 — — WO disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 — — EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 — — WO disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 — — WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 — — US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 — — US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ DDB1 3192/4885CRBN 1184/4885NR1H2 3082/4885
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS DDB1 710/4885CRBN 3313/4885NR1H2 1001/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE DDB1 3291/4885CRBN 1030/4885NR1H2 2585/4885
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 DDB1 369/4885CRBN 299/4885NR1H2 1061/4885
US-20230212127-A1 LIVER X RECEPTOR (LXR) MODULATORS NR1H2, NR1H3, NR1H4 DDB1 1372/4885CRBN 3184/4885NR1H2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.